Estelamari Rodriguez

2 weeks ago | onclive.com | Estelamari Rodriguez |Tarek Mekhail |Balazs Halmos |Susan Scott |Julie R. Brahmer |Corey J Langer | +1 more

CommentaryVideoApril 30, 2025Author(s):,Fact checked by:,Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Jan 6, 2025 | onclive.com | Estelamari Rodriguez

Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care. Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care.

Feb 2, 2024 | onclive.com | Estelamari Rodriguez

February 2, 2024Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

May 18, 2023 | futuremedicine.com | Edgardo S. Santos |Estelamari Rodriguez |Boca Raton

Lung Cancer ManagementAhead of PrintPlain Language Summary of PublicationOpen AccessAbstractWhat is this article about? This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung. What is SCC of the lung? SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking.

Apr 19, 2023 | onclive.com | Estelamari Rodriguez

Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center, discusses the benefits of the TKIs afatinib (Gilotrif) and osimertinib (Tagrisso) in patients with lung cancer with uncommon EGFR mutations. In patients with lung cancer, EGFR mutations can fall into several categories.